NCT03954171招募中不适用
Platino-resistance in Ovarian Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 600
- 试验地点
- 1
- 主要终点
- The rate of patients alive without progression
研究概览
简要总结
Prospective, monocentric study aiming to identify factors involved in platinum based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages).
Patients will receive treatment (platinum based-chemotherapy) according to the standard practices.
A prospective database and an associated biological collection will be performed during 5 years:
- For each patient: clinical, biological, epidemiological and therapeutic treatment data will be collected during the standard therapeutic care.
- Biological samples (blood samples, tumor biopsy specimens and ascites samples) will be collected for all patients. These samples will be collected at the same time as those taken in standard practice (no additional biopsy will be performed for the study).
Study participation of each patient will be 5 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years old
- •Epithelial ovarian cancer at initial diagnosis (all stages)
- •Curative treatment (exeresis surgery) not yet initiated excepted neo-adjuvant treatment
- •Indication of platinum based-chemotherapy
- •Patient affiliated to the french social security system
- •Patient must provide written informed consent prior to inclusion in the study and any study-specific procedure
排除标准
- •Non-epithelial ovarian tumor, borderline ovarian tumor
- •Patient with recurrent disease
- •Exploratory surgery not performed at the "Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT-O)"
- •Pregnant or breastfeeding women
- •Any psychological, familial, geographical or sociological condition potentially preventing the medical follow-up and/or study procedures
- •Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
结局指标
主要结局
The rate of patients alive without progression
时间窗: 5 years for each patient
次要结局
- The time to onset of platinum based-chemotherapy resistance(5 years for each patient)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian CancerOvarian CancerNCT03587129First Affiliated Hospital of Harbin Medical University1
尚未招募
不适用
Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian CancerCytoreductive SurgeryNCT05633199Women's Hospital School Of Medicine Zhejiang University140
已完成
3 期
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian CancerOvarian CancerNCT04908787Jiangsu Simcere Pharmaceutical Co., Ltd.421
终止
2 期
Cabazitaxel in Platinum Refractory Ovarian CancerOvarian CancerNCT01747239Vejle Hospital4
已完成
2 期
Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasmsACTRN12610000796088niversity of Sydney333